Jefferies analyst Roger Song initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $45 price target The firm sees meaningful upside potential in the shares from the Phase 2a ORKA-001 study in plaque psoriasis with a readout in the second half of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
- Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
- ORKA Earnings this Week: How Will it Perform?
- Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know
- Oruka Therapeutics initiated with a Buy at Guggenheim